Rivas Capital

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

GreenLight Biosciences, Inc. is a biotechnology company headquartered in Medford, Massachusetts, with an additional location in North Carolina. Founded in 2008, the company specializes in developing RNA-based solutions for agricultural and pharmaceutical purposes. It offers a proprietary technology platform that enables the efficient and cost-effective production of high-quality RNA, facilitating advancements in vaccine development, pandemic response, crop management, and the protection of pollinators. GreenLight develops mRNA-based vaccine candidates, including those aimed at preventing SARS-CoV-2 infections, and engages in collaborative efforts with industry leaders to further enhance its offerings. Through its innovative approach, GreenLight aims to contribute significantly to sustainable global development and food security.

Clarify Health Solutions, Inc. is a healthcare technology company based in San Francisco, California, that provides a software and analytics platform designed to enhance patient care delivery. The platform, known as Clarify Episode, facilitates real-time engagement among patients, clinicians, and care teams by delivering critical information and insights. It stratifies patients based on various characteristics, monitors their progress, and identifies potential complications early, prompting timely interventions. Key offerings include Care Pilot, a mobile and browser-based tool that empowers patients in their care journey; Care Connect, which enables clinicians to monitor and analyze patient data; and Care Prism, which delivers real-time business and productivity analytics for management. The company's solutions aim to improve efficiency, satisfaction, and engagement for patients, care teams, hospitals, and payers. Clarify Health Solutions was incorporated in 2015 and maintains a strategic alliance with Leidos.

NextRNA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company focuses on developing targeted therapeutics by discovering novel non-coding ribonucleic acids (ncRNAs) linked to various diseases. Utilizing an innovative discovery platform, NextRNA identifies and modulates RNA-binding proteins associated with disease functions of ncRNAs. This approach aims to disrupt the interactions between disease-related ncRNAs and their protein partners, thereby enabling medical practitioners to address and potentially cure a range of diseases.

GreenLight Biosciences, Inc. is a biotechnology company headquartered in Medford, Massachusetts, with an additional location in North Carolina. Founded in 2008, the company specializes in developing RNA-based solutions for agricultural and pharmaceutical purposes. It offers a proprietary technology platform that enables the efficient and cost-effective production of high-quality RNA, facilitating advancements in vaccine development, pandemic response, crop management, and the protection of pollinators. GreenLight develops mRNA-based vaccine candidates, including those aimed at preventing SARS-CoV-2 infections, and engages in collaborative efforts with industry leaders to further enhance its offerings. Through its innovative approach, GreenLight aims to contribute significantly to sustainable global development and food security.

Comgy GmbH, founded in 2017 and based in Berlin, Germany, specializes in digital metering solutions for the housing and energy sectors. The company offers a range of products including a sub-metering solution that enables users to efficiently read meters, alongside sensors and smoke alarms. Comgy provides a Meter Gateway Management application, which acts as a control center for remote device configuration and data processing, as well as a Meter Installation Manager application for the digital registration of radiator measurements, supported by photographic documentation. Additionally, its Polyglot gateway facilitates encrypted communication between meters, sensors, and its customer platform. Comgy's technology enhances the measurement, visualization, and billing processes of heat, water, and electricity consumption in real estate, promoting transparency and facilitating energy savings.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Clarify Health Solutions, Inc. is a healthcare technology company based in San Francisco, California, that provides a software and analytics platform designed to enhance patient care delivery. The platform, known as Clarify Episode, facilitates real-time engagement among patients, clinicians, and care teams by delivering critical information and insights. It stratifies patients based on various characteristics, monitors their progress, and identifies potential complications early, prompting timely interventions. Key offerings include Care Pilot, a mobile and browser-based tool that empowers patients in their care journey; Care Connect, which enables clinicians to monitor and analyze patient data; and Care Prism, which delivers real-time business and productivity analytics for management. The company's solutions aim to improve efficiency, satisfaction, and engagement for patients, care teams, hospitals, and payers. Clarify Health Solutions was incorporated in 2015 and maintains a strategic alliance with Leidos.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company founded in 2016 and located in Boston, Massachusetts. The company specializes in developing treatments for peripheral neuropathies, hemoglobinopathies, and specific oncology indications. Its innovative approach focuses on regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy's lead product, ricolinostat, serves as a selective HDAC6 inhibitor, which enables the treatment of conditions such as sickle cell disease and beta-thalassemia. Through its targeted therapeutic strategies, Regenacy aims to address significant unmet medical needs in various disease areas.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

Gamalon Inc., established in 2013 and headquartered in Boston, Massachusetts, specializes in statistical machine learning solutions. The company focuses on Bayesian probabilistic programming languages for machine learning, aiming to accelerate this process. Gamalon's AI-based technology can convert streams of text paragraphs into structured data rows by linking, enabling businesses to train their systems with fewer data points while maintaining the accuracy of exhaustively trained neural networks. This platform helps enterprises understand their customers better and take impactful actions by interpreting and summarizing customer messages, making predictions, and facilitating meaningful business decisions.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for retinal diseases. The company's lead product candidate, KSI-301, is a vascular endothelial growth factor (VEGF)-biological agent currently undergoing Phase 1b clinical trials for the treatment of wet age-related macular degeneration and diabetic retinopathy. Additionally, Kodiak is advancing KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate designed to address inflammation and abnormal blood vessel growth associated with retinal vascular diseases. The early research pipeline also includes KSI-601, a triplet inhibitor targeting dry age-related macular degeneration. Founded in 2009 and headquartered in Palo Alto, California, Kodiak Sciences was previously known as Oligasis, LLC, before rebranding in 2015.

ReviveMed Inc is a precision-medicine company based in Cambridge, Massachusetts, founded in 2016. The company specializes in a platform that utilizes data from small molecules, or metabolites, applying a network-based machine learning algorithm to conduct integrative analyses of untargeted metabolomic data alongside other extensive molecular information, such as data from genes, proteins, drugs, and diseases. This innovative approach transforms metabolomic data into actionable insights, facilitating the development of in-house therapeutics tailored for patients suffering from liver diseases and related conditions. ReviveMed aims to enhance health outcomes by unlocking the potential of metabolomics in medical research and treatment.

GreenLight Biosciences, Inc. is a biotechnology company headquartered in Medford, Massachusetts, with an additional location in North Carolina. Founded in 2008, the company specializes in developing RNA-based solutions for agricultural and pharmaceutical purposes. It offers a proprietary technology platform that enables the efficient and cost-effective production of high-quality RNA, facilitating advancements in vaccine development, pandemic response, crop management, and the protection of pollinators. GreenLight develops mRNA-based vaccine candidates, including those aimed at preventing SARS-CoV-2 infections, and engages in collaborative efforts with industry leaders to further enhance its offerings. Through its innovative approach, GreenLight aims to contribute significantly to sustainable global development and food security.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Gamalon Inc., established in 2013 and headquartered in Boston, Massachusetts, specializes in statistical machine learning solutions. The company focuses on Bayesian probabilistic programming languages for machine learning, aiming to accelerate this process. Gamalon's AI-based technology can convert streams of text paragraphs into structured data rows by linking, enabling businesses to train their systems with fewer data points while maintaining the accuracy of exhaustively trained neural networks. This platform helps enterprises understand their customers better and take impactful actions by interpreting and summarizing customer messages, making predictions, and facilitating meaningful business decisions.

Gamalon Inc., established in 2013 and headquartered in Boston, Massachusetts, specializes in statistical machine learning solutions. The company focuses on Bayesian probabilistic programming languages for machine learning, aiming to accelerate this process. Gamalon's AI-based technology can convert streams of text paragraphs into structured data rows by linking, enabling businesses to train their systems with fewer data points while maintaining the accuracy of exhaustively trained neural networks. This platform helps enterprises understand their customers better and take impactful actions by interpreting and summarizing customer messages, making predictions, and facilitating meaningful business decisions.

Force of Nature manufactures electronic appliances designed to create a cleaning solution using basic ingredients found at home.

N12 Technologies, Inc. is a manufacturer of advanced nano-composite materials, specializing in production-scale nanotechnology for the aerospace, automotive, and consumer goods sectors. The company offers innovative products such as NanoStitch, which reinforces the interlaminar region of composite materials, and the Surface Layer System, designed to enhance thermal and electrical conductivity for various applications. N12's technology, developed through research licensed from MIT, utilizes vertically-aligned carbon nanotube (VACNT) forests to improve material properties such as shear strength, fatigue life, and impact resistance. This enables clients to achieve greater weight savings and toughness without altering existing fabrication processes. Founded in 2012, N12 Technologies is based in Somerville, Massachusetts, and serves a diverse range of industries, including sporting goods and aeronautics.

Zipline Inc. is a California-based company that specializes in the design, manufacture, and operation of drones for delivering essential medical supplies. Founded in 2011 and headquartered in Half Moon Bay, the company aims to ensure that every individual has immediate access to vital medical products, including vaccines, medicines, and blood. Zipline operates a sophisticated autonomous logistics network, utilizing proprietary fixed-wing drones to facilitate rapid deliveries to hospitals and health centers, particularly in remote areas. The company not only designs and tests its drones but also assembles the technology that underpins its distribution capabilities, thereby enhancing the efficiency and effectiveness of medical supply delivery.

Aircuity, Inc. is a manufacturer of intelligent measurement solutions aimed at enhancing energy efficiency and indoor environmental quality in various settings, including commercial offices, educational institutions, healthcare facilities, and sports arenas. Founded in 2000 and headquartered in Newton, Massachusetts, the company offers a range of products, including the Sensor Suite, which utilizes a scalable architecture for monitoring multiple indoor environmental parameters. Their offerings also include specialized sensors for evaluating conditions such as temperature and air quality, along with a comprehensive Information Management System for network oversight. Aircuity's technology focuses on demand control ventilation, allowing for real-time adjustments based on internal conditions, thereby optimizing operational performance and safety. The company markets its products through various sales channels across numerous countries, ensuring a global reach in supporting energy conservation and improving indoor environments.

N12 Technologies, Inc. is a manufacturer of advanced nano-composite materials, specializing in production-scale nanotechnology for the aerospace, automotive, and consumer goods sectors. The company offers innovative products such as NanoStitch, which reinforces the interlaminar region of composite materials, and the Surface Layer System, designed to enhance thermal and electrical conductivity for various applications. N12's technology, developed through research licensed from MIT, utilizes vertically-aligned carbon nanotube (VACNT) forests to improve material properties such as shear strength, fatigue life, and impact resistance. This enables clients to achieve greater weight savings and toughness without altering existing fabrication processes. Founded in 2012, N12 Technologies is based in Somerville, Massachusetts, and serves a diverse range of industries, including sporting goods and aeronautics.

Lumicell, Inc. is a company focused on developing and marketing innovative image-guided solutions for cancer surgery. It specializes in technology that provides real-time visual feedback to surgeons regarding the presence of residual cancer cells within the tumor bed. The core of Lumicell's system includes a handheld imaging device and a cancer-specific optical contrast agent that illuminates cancer cells, allowing for thorough removal of cancerous tissue during surgery. The company's lead product is currently undergoing clinical trials, particularly in breast cancer surgery, where it aims to reduce the rates of positive margins and repeat surgeries while preserving healthy tissue. Additionally, Lumicell's technology is being explored for use in other types of cancer, such as colorectal cancer and pancreatic cancer. Founded in 2008 and based in Wellesley, Massachusetts, Lumicell has demonstrated a strong safety profile for its imaging agent and has not missed any cancer detections in clinical studies to date.